PMID- 16132498
OWN - NLM
STAT- MEDLINE
DCOM- 20060404
LR  - 20181113
IS  - 0167-594X (Print)
IS  - 0167-594X (Linking)
VI  - 76
IP  - 2
DP  - 2006 Jan
TI  - Targeted tumor cell death induced by autologous tumor-specific T lymphocyte 
      recognition of wild-type p53-derived peptides.
PG  - 99-104
AB  - Autologous tumor-specific T lymphocyte (ATTL) lines were derived from the 
      peripheral blood mononuclear cells (PBMC) of a healthy volunteer with human 
      leukocyte antigen (HLA) -A*0201. These lines were achieved using interleukins 
      -1beta, -2, -4, and -6 and the p53-based peptide from the 264-272 sequence of the 
      wild-type p53 protein with a strong affinity against HLA-A*0201.;The frequencies 
      of CD3+, CD4+, and CD8+ lymphocytes were 94-96%, 30-34%, and 69-74%, 
      respectively. ATTLs killed most of the T2 cells pulsed with p53-derived peptide, 
      but not against the T2 cells non-pulsed or pulsed with an irrelevant peptide. 
      ATTLs also killed TKB-14 cells, which have been derived from human glioblastoma 
      multiforme, and exhibited HLA-A*0201 molecule and immunohistochemical 
      accumulation of p53 protein. These cytotoxic activities were inhibited by 
      anti-CD3, anti-CD8, and anti-class I antibodies. These findings suggested that 
      these ATTL lines might include CTL populations, which could recognize p53-derived 
      peptide on HLA-A*0201 and the p53-based peptide may play as an antigen on 
      HLA-A*0201. When tumor antigens would be more analyzed in the future, ATTL could 
      be induced without the primary-cultured cells from tumor tissue and could be 
      applied for cancer therapy.
FAU - Tsurushima, Hideo
AU  - Tsurushima H
AD  - Faculty of Medicine, Department of Neuro Surgery, University of the Ryukyus, 
      Okinawa, Japan. hideo-tsurushima@aist.go.jp
FAU - Yoshii, Yoshihiko
AU  - Yoshii Y
FAU - Leong, Kam W
AU  - Leong KW
FAU - Ohno, Tadao
AU  - Ohno T
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Antigens, Surface)
RN  - 0 (CD3 Complex)
RN  - 0 (HLA-A Antigens)
RN  - 0 (Peptides)
RN  - 0 (Tumor Suppressor Protein p53)
SB  - IM
MH  - Antigens, Surface/immunology
MH  - Brain Neoplasms/*immunology/*pathology
MH  - CD3 Complex/immunology
MH  - CD4-Positive T-Lymphocytes/immunology
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Cell Death/*physiology
MH  - Cell Line, Tumor
MH  - Cells, Cultured
MH  - Flow Cytometry
MH  - HLA-A Antigens/immunology
MH  - Humans
MH  - Immunohistochemistry
MH  - K562 Cells
MH  - Monocytes/metabolism
MH  - Peptides/immunology
MH  - Phenotype
MH  - T-Lymphocytes/*immunology
MH  - Tumor Suppressor Protein p53/*immunology
EDAT- 2005/09/01 09:00
MHDA- 2006/04/06 09:00
CRDT- 2005/09/01 09:00
PHST- 2005/09/01 09:00 [pubmed]
PHST- 2006/04/06 09:00 [medline]
PHST- 2005/09/01 09:00 [entrez]
AID - 10.1007/s11060-005-4172-6 [doi]
PST - ppublish
SO  - J Neurooncol. 2006 Jan;76(2):99-104. doi: 10.1007/s11060-005-4172-6.